Short Interest in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Drops By 60.9%

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 29,300 shares, a decrease of 60.9% from the January 31st total of 74,900 shares. Based on an average trading volume of 332,300 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company’s stock are short sold.

Institutional Trading of Chemomab Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Sphera Funds Management LTD. bought a new position in shares of Chemomab Therapeutics during the third quarter worth approximately $1,907,000. Virtu Financial LLC bought a new position in shares of Chemomab Therapeutics during the fourth quarter worth approximately $26,000. Finally, XTX Topco Ltd increased its stake in shares of Chemomab Therapeutics by 63.8% during the fourth quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after purchasing an additional 9,706 shares during the period. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Up 3.7 %

NASDAQ:CMMB opened at $1.68 on Friday. The stock’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $1.74. The firm has a market capitalization of $24.12 million, a price-to-earnings ratio of -1.68 and a beta of 0.66. Chemomab Therapeutics has a 12-month low of $0.58 and a 12-month high of $2.55.

Analysts Set New Price Targets

Several research firms recently issued reports on CMMB. Oppenheimer reiterated an “outperform” rating and set a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th. Maxim Group upped their price objective on Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, February 20th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).